Drug Profile
Deupirfenidone - PureTech Health
Alternative Names: Deuterated pirfenidone; Deuterium-substituted pirfenidone; LYT-100; LYT-100-COV; LYT-100-ILD; LYT-100-LYMPH; Pirfenidone deuterated; SD-560Latest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Auspex Pharmaceuticals
- Developer PureTech Health
- Class Anti-infectives; Anti-inflammatories; Antifibrotics; Organic deuterium compounds; Pyridones; Small molecules
- Mechanism of Action Collagen inhibitors; Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis; Lymphoedema
- Discontinued Post acute COVID 19 syndrome
Most Recent Events
- 16 Apr 2024 PureTech Health completes enrollment in a phase IIb ELEVATE trial in Idiopathic pulmonary fibrosis (Treatment-naive) in USA, Argentina, Chile, Colombia, Georgia, Greece, India, South Korea, Malaysia, Mexico, Philippines, Romania, South Africa, and Thailand (PO) (NCT05321420)
- 20 Dec 2023 PureTech Health plans a phase-III trial for Idiopathic pulmonary fibrosis in USA
- 11 Oct 2023 Pharmacokinetics and adverse events data from a phase I trial in Idiopathic pulmonary fibrosis released by PureTech